United States · FDA National Drug Code directory
ABRILADA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0025-0333_0989d777-c225-46a6-854e-01bdf4f19679
- Product NDC
- 0025-0333
- Form
- KIT
- Composition / generic term
- adalimumab-afzb
- Labeler
- Pfizer Laboratories Div Pfizer Inc
- Marketing category
- BLA
- Marketing start / end (source format)
- 20231214
- Source listing expiry
- 20271231
Source-listed ingredients
Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.
These values do not establish equivalence or a dose recommendation.
Packages
- 2 KIT in 1 CARTON (0025-0333-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (0025-0329-01) * 1 mL in 1 PACKET (0069-1111-01) · 0025-0333-02
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →